- Home
- CHN vs CGEN Comparison
CHN vs CGEN Comparison
Compare CHN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- CGEN
- Stock Information
- Founded
- CHN 1992
- CGEN 1993
- Country
- CHN United States
- CGEN Israel
- Employees
- CHN N/A
- CGEN N/A
- Industry
- CHN Investment Managers
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHN Finance
- CGEN Health Care
- Exchange
- CHN Nasdaq
- CGEN Nasdaq
- Market Cap
- CHN 144.1M
- CGEN 167.4M
- IPO Year
- CHN N/A
- CGEN 2000
- Fundamental
- Price
- CHN $15.11
- CGEN $1.59
- Analyst Decision
- CHN
- CGEN
- Analyst Count
- CHN 0
- CGEN 0
- Target Price
- CHN N/A
- CGEN N/A
- AVG Volume (30 Days)
- CHN 31.8K
- CGEN 156.2K
- Earning Date
- CHN 01-01-0001
- CGEN 08-05-2025
- Dividend Yield
- CHN 0.19%
- CGEN N/A
- EPS Growth
- CHN N/A
- CGEN N/A
- EPS
- CHN N/A
- CGEN N/A
- Revenue
- CHN N/A
- CGEN $27,589,000.00
- Revenue This Year
- CHN N/A
- CGEN N/A
- Revenue Next Year
- CHN N/A
- CGEN $173.80
- P/E Ratio
- CHN N/A
- CGEN N/A
- Revenue Growth
- CHN N/A
- CGEN N/A
- 52 Week Low
- CHN $9.00
- CGEN $1.13
- 52 Week High
- CHN $12.98
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- CHN 74.35
- CGEN 44.35
- Support Level
- CHN $14.69
- CGEN $1.66
- Resistance Level
- CHN $14.88
- CGEN $1.74
- Average True Range (ATR)
- CHN 0.21
- CGEN 0.10
- MACD
- CHN 0.00
- CGEN -0.02
- Stochastic Oscillator
- CHN 96.30
- CGEN 11.54
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.